DUKE STREET BIO
Duke Street Bio develops medical drugs intended to provide improved treatment to cancer patients. It was founded in 2020 and is based in London, England.
DUKE STREET BIO
Social Links:
Industry:
Biopharma Biotechnology Life Science Medical
Founded:
2020-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.dukestbio.com
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.44 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
AANDSA Pharm
AANDSA Pharm develop a controlled drug delivery hydrogel patch for psoriasis.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
PlantExt
PlantExt develops medical cannabis products intended to provide anti-inflammatory remedies.
Sentai
Sentain is learning for contextual conversation that provides timely alerts for the important things.
Thiakis
Thiakis develop novel analogues of naturally occurring hormones for the treatment of obesity and co-morbidities.
Wockhardt Bio AG
Wockhardt Bio develops, manufactures and markets pharmaceutical and bio-pharmaceutical formulations.
Current Employees Featured
Official Site Inspections
http://www.dukestbio.com
- Host name: 45.87.81.83
- IP address: 45.87.81.83
- Location: Republic of Lithuania
- Latitude: 56
- Longitude: 24
- Timezone: Europe/Vilnius
More informations about "Duke Street Bio"
About | Duke Street Bio - dukestbio.com
Duke Street Bio is focused on exploiting tumour genetic vulnerabilities by developing the next generation of molecules targeting DNA Damage Repair (DDR) deficiencies in cancer.See details»
People | Duke Street Bio - dukestbio.com
Duke Street Bio draws on the expertise and experience of its Scientific Advisory Board comprised of an extensive network of internationally-renowned scientists, physicians and key opinion leadersSee details»
Duke Street Bio - Crunchbase Company Profile
Duke Street Bio develops medical drugs intended to provide improved treatment to cancer patients. It was founded in 2020 and is based in London, England.See details»
Duke Street Bio - LinkedIn
Duke Street Bio is focused on exploiting tumour genetic vulnerabilities and harnessing the natural power of the body’s immune system to fight cancer.See details»
Duke Street Bio - PitchBook
Sep 9, 2020 Duke Street Bio General Information Description. Developer of medical drugs intended to provide improved treatment to cancer patients. The company focuses on …See details»
Duke Street Bio - VentureRadar
"Duke Street Bio is focused on reprogramming cancer cell and tumour microenvironment biology to unleash the natural power of the body’s immune system to fight cancer.See details»
Duke Street Bio granted approval by European Medicines Agency …
For more information about Duke Street Bio and our upcoming clinical trial, please visit www.dukestbio.com. About Duke Street Bio: Duke Street Bio is at the forefront of developing …See details»
DUKE STREET BIO LIMITED - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for DUKE STREET BIO LIMITED of LONDON. Get the latest business insights from Dun & Bradstreet.See details»
DUKE STREET BIO LIMITED - Companies House
DUKE STREET BIO LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business …See details»
First Patient Dosed in Phase I Trial - dukestbio.com
6 days ago Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to announce that the first patient has been dosed in a …See details»
Duke Street Bio Announces Appointment of Chief Medical Officer
Mar 28, 2023 Duke Street Bio, a UK-based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today announced the strengthening of its executive …See details»
Duke Street Bio - VentureRadar
Similar Companies: Website: https://dukestbio.com/ Duke Street Bio is focused on reprogramming cancer cell and tumour microenvironment biology to unleash the natural ...See details»
Duke Street Bio enters stage with next-generation cancer therapies
May 25, 2022 The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells.See details»
Science | Duke Street Bio - dukestbio.com
First-generation PARP1 inhibitors have provided significant therapeutic benefit to patients whose tumours exhibit homologous repair deficiencies including BRCA mutations, however their use …See details»
dukestbio.com Reviews | check if site is scam or legit| Scamadviser
Check dukestbio.com with our free review tool and find out if dukestbio.com is legit and reliable. Need advice? Report scams Check Scamadviser! Report a Scam Help & Info API & Data Feed en Deutsch English Español Français Italiano 日本 Nederlands Português Romanian Russian Ukrainian 简体ä¸æ–‡ en DeutschSee details»
Duke Street Bio Granted Approval by European Medicines Agency …
Sep 24, 2024 Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial. September 24, 2024 – Clinical Trials, Drug …See details»
Duke Street Bio Granted Approval by European Medicines Agency …
[London, 24th September 2024] – Life Science Newswire – Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to …See details»
Duke Street Bio - EU-Startups
Duke Street Bio develops medical drugs intended to provide improved treatment to cancer patients. Duke Street Bio is focused on reprogramming cancer cell and tumour …See details»
Duke Street Bio - Company Profile - Tracxn
Duke Street Bio - Developer of precision medicine-based cancer therapies. Founded by Barry McGuinness and Phill Cowley in the year 2019. Duke Street Bio has 620 competitors.See details»